mesothelioma

Mesothelioma Treatment Options for Malignant Mesothelioma

Mesothelioma treatment options for malignant mesothelioma can relieve pain and provide hope for the future. In many cases, new mesothelioma treatment options can increase mesothelioma life expectancy beyond original expectations. Even if advanced malignant mesothelioma has reached a seemingly incurable stage, participating in clinical trials gives a breath of hope to the future generations of mesothelioma cancer patients.

Treatment for malignant mesothelioma can start with surgery, although this is not always recommended in mesothelioma treatment options since older patients may have a difficult time with surgery. The objective is to remove the tumor, or at least most of it, and slow down the disease. With advanced mesothelioma, the tumor has often tragically spread throughout the body and has invaded life-giving organs, making surgery more risky than living with cancer itself. However in the early stages of malignant mesothelioma, a localized tumor is more likely to be successfully removed.

Radical surgery is a mesothelioma treatment option for advanced malignant mesothelioma that has been used in small clinical trials, but has resulted in almost half the patients (48%) living at least five years past their predetermined mesothelioma life expectancy date. “Extrapleural pneumonectomy” involves removing the internal body parts that mesothelioma cancer cells love to invade. Surgery removes the parietal pleura (pleural mesothelioma), the pericardium (pericardial mesothelioma) and the diaphragm, as well as the removal of a lung. This surgery is combined with pre and post operative chemotherapy and radiotherapy. Cancer Research UK is funding a “MARS” clinical trial (mesothelioma and radical surgery) to formally undergo pilot testing. Since the patients must be followed for five years, the results are not yet available and the success of these mesothelioma treatment options has yet to be discovered. UK medical reports do claim that US trial results have thus far demonstrated that a heavier dose of radiotherapy after the EPP surgery extends mesothelioma life expectancy.

Mesothelioma treatment options almost always include chemotherapy. Progress is seen in mesothelioma treatment when chemotherapy is combined with drug therapy. There are clinical trials for mesothelioma treatment options around the world that are seeking to find the chemotherapy and drug mix that can prolong mesothelioma life expectancy. Clinical trials are listed at many cancer organizations and research hospitals, and many seek mesothelioma patients wanting mesothelioma treatment options for advanced malignant mesothelioma. In advanced malignant mesothelioma, participating in a clinical trial can be a lifesaving mesothelioma treatment option.

Mesothelioma treatment options for advanced malignant mesothelioma can also be found in clinical trials for anti-angiogenic therapy. Anti-angiogenic mesothelioma treatment options are biological therapies that revolve around blood vessel growth. A cancer needs its own blood supply to grow. Two primary chemicals contribute to growth, VEGF and FGF-2. Mesothelioma patients with advanced malignant mesothelioma have higher levels of VEGF compared to patients suffering from other cancers. The theory the clinical trials are hoping to prove is that blocking VEFG will stop the blood vessel growth that supports the cancer growth.

Mesothelioma treatment options for malignant mesothelioma also includes clinical trials in phototherapy, immunotherapy, gene therapy and other therapies. Medical specialists are scrambling to find the mesothelioma treatment options for malignant mesothelioma that can protect and cure the projected increase in mesothelioma patients of the future. Participating in clinical trials can extend mesothelioma life expectancy and provide hope for future generations.

Mesothelioma Stages and Mesothelioma Staging Systems

Mesothelioma stages are categorized in the medical community for evaluative benefit for the physician, the medical institution, participation in clinical trials, and advancements in mesothelioma treatment options. Staging systems are used to define mesothelioma stages; however, mesothelioma stages are far more descriptive for pleural mesothelioma than for peritoneal mesothelioma or pericardial mesothelioma. Mesothelioma staging systems have changed over time. As medical knowledge increases, mesothelioma staging systems advance.

By sectioning a progressive disease into stages, doctors can evaluate mesothelioma treatment options that have been proven successful. By defining mesothelioma stages in a universal staging system, international mesothelioma life expectancy statistics can be gathered. When a staging system gains international acceptance, it contributes greatly to the advancement of mesothelioma treatment options. Grouping similar variables for evaluation is beneficial to developing mesothelioma treatment options for different mesothelioma stages.

In 1976 the Butchart staging system identified four mesothelioma stages for diffuse pleural malignant mesothelioma by location. At stage one, the tumor is in one side of the pleural lining. At stage two, the tumor is malignant and has entered both lungs, and has the potential to spread. In stage three of Butchart’s mesothelioma stages, the tumor has entered the peritoneum (abdomen region), and at stage four, the cancer has spread through the blood stream.

It was simple, thus gained acceptance. However, it fails to address crucial issues. Medical experts suggest it fails to make survival correlations with mesothelioma stages. The Butchart mesothelioma staging system in its originality is obsolete for mesothelioma life expectancy statistics, however other mesothelioma stages have been developed from it, and many cancer institutions modify it for their evaluative purposes.

In the 1980s Chahinian added detailed tumor stages, lymph node stages and metastases stages to the pleural mesothelioma staging system. This staging system is referred to as TNM and is used within elaborative staging systems. In 1990 the UICC (Union Internationale Contre le Cancer) expounded on Chahinian’s mesothelioma stages. The Butchart, Chahinian and UICC mesothelioma staging systems were based on specific institution experience.

In 1999 the Bingham Hospital introduced a pleural mesothelioma surgical staging system in the Journal of Thoracic and Cardiovascular Surgery. The IMIG (International Mesothelioma Interest Group) in a 1995 Journal of Chest from the American College of Chest Physicians proposed international acceptance for a detailed universal staging system. This staging system demands precise tumor location, and is based on TNM and the International Lung Cancer Staging System.

Medical institutions will use the mesothelioma stages and staging system practical for their internal evaluative purposes. But the mesothelioma patient should be aware when discussing mesothelioma life expectancy and prognosis that mesothelioma staging systems differ, and staging systems still undergo scrutiny. No staging system includes all variables for treatment and prognosis. Factors such as tumor subtypes can make a significant difference in prognosis.

In its basic form, mesothelioma has two stages – localized and advanced. In most staging systems, localized mesothelioma is considered stage one. Stages two through four are advanced mesothelioma stages. Mesothelioma stages are generally defined by location, the severity of the tumor, or surgical needs. The stages of mesothelioma are dependent on the staging system used.

Mesothelioma stages are important considerations in treatment and prognosis. An accepted universal mesothelioma staging system can expedite medical research to find effective mesothelioma treatment options. Advances in clinical research will continue to contribute to the development of defining mesothelioma stages until precise correlations can be made. Until then, staging systems are a universal answer to evaluating mesothelioma treatment.

California Mesothelioma Laws And California Mesothelioma Lawyers

Finding a highly qualified and competent California mesothelioma attorney involves a little investigation. Newly diagnosed victims of Mesothelioma in California often have ample questions involving their health, their future, and their lawful recourses in the event of a mesothelioma diagnosis. The facts of mesothelioma are not easy to hear, nor are they easy to deal with. While a Mesothelioma doctor is equipped to answer medical and health questions as they relate to Mesothelioma, only a qualified Mesothelioma attorney is capable of answering questions that are associated with the legal ramifications of a mesothelioma diagnosis.

California mesothelioma victims are encouraged to make a list of questions that they feel they need answers to, one list for their Mesothelioma physician and another list for their attorney. The top ten questions to ask a California mesothelioma attorney have been suggested here, but there will be many more questions regarding a Mesothelioma case.

1. It is vital to contact a Mesothelioma lawyer as quickly as possible as many states have complicated regulations concerning Mesothelioma lawsuits. The first question to ask a qualified Mesothelioma lawyer is whether or not you qualify to file a Mesothelioma lawsuit. This of course will involve divulging all the information possible to allow the Mesothelioma lawyer to determine if you qualify to file a Mesothelioma lawsuit.

2. Some California mesothelioma lawyers are already involved with other Mesothelioma lawsuits or Mesothelioma settlements which may preclude them from taking on any new cases. It is possible that you may qualify for a class action lawsuit or perhaps an individual Mesothelioma lawsuit, depending on the circumstances. Mesothelioma patients need to inquire whether their case would be handled as an individual case or as part of a class action Mesothelioma lawsuit, and which would benefit them the most.

3. Knowing that your potential Mesothelioma lawyer has ample actual courtroom experience is a highly important part of hiring a Mesothelioma lawyer. It is perfectly acceptable to inquire with your potential Mesothelioma lawyer about their prior Mesothelioma and courtroom experience. Mesothelioma lawsuits are not the type of lawsuits you want a newbie cutting their teeth on, there is simply too much at stake.

4. California mesothelioma lawsuits tend to be large cases with a lot of complicated laws and circumstances to navigate. A Mesothelioma attorney needs to have ample support and resources to assist in the research and argument process. You will want to ask the Mesothelioma attorney how many Mesothelioma cases are in the firm, how many Mesothelioma expert lawyers are in the firm, and how much extra support services they can receive from the other California mesothelioma attorneys in the law firm.

5. Mesothelioma victims tend to be victimized by the contraction of the disease and are often very sensitive to other people’s feelings, including their Mesothelioma lawyer’s feelings. Asking questions that validate their experience is a good thing, and is not offensive to a Mesothelioma lawyer. If your potential Mesothelioma attorney reacts to questions with offense, it is not in your best interest to hire them. Asking them about their track record with Mesothelioma cases, how many went to trial versus how many of them were settled, as well as the results of each case is a reasonable line of questioning.

6. It is rarely in the best interest of the Mesothelioma victim for their case to be split between multiple law firms. Asking whether your lawsuit will be handled in house or if there is the possibility of splitting the case between law firms is a question of relative importance.

7. The vast majority of California mesothelioma cases are handled on a contingency basis, which means the attorney gets paid a percentage of what he or she is able to win on the Mesothelioma victim’s behalf. If the case goes nowhere, the Mesothelioma lawyer typically doesn’t get paid. The percentage of the Mesothelioma award or the Mesothelioma settlement which typically goes to the representing Mesothelioma lawyer is between 30 and 40 percent.

8. Asking your California mesothelioma lawyer to describe the process of a lawsuit will enable you to understand the process which you are about to enter as well as inform you of how well your Mesothelioma lawyer communicates..

9. It is important to understand how long the Mesothelioma lawyer will need for research and how much information he or she will need from the Mesothelioma victim and the Mesothelioma doctor. Television has given us the impression that lawsuits and court proceedings happen quickly. They don’t it takes time, and for a Mesothelioma victim, time is very precious.

10. California mesothelioma laws may vary by county. Establishing the jurisdiction that the Mesothelioma case will be tried is vital. Often it is tried in the county which the exposure to asbestos took place. Your Mesothelioma lawyer will have to have access to that region.

Mesothelioma Mesomark Blood Test

MESOSELIOMA MESOMARK BLOOD TEST
The Food and Drug Administration (FDA) approved the MESOMARK assay to help monitor response to treatment in malignant mesothelioma patients. The MESOMARK test signifies the beginning of a new era in monitoring mesothelioma malignancies,” said Dr. W. Jeffrey Allard, vice president and chief scientific officer of Fujirebio Diagnostics. “As the first in-vitro test for patients with this aggressive disease, it will enable doctors to more accurately detect recurrence and monitor treatment of patients.”
The MESOMARK Assay test kit was developed to measure levels of a biomarker, mesothelin, in serum. Biomarkers are substances found in higher-than-normal concentrations in the blood, urine or body tissues of patients with certain types of cancers. The test may be used to monitor patients confirmed as having mesothelioma, for recurrence in patients following surgery, or for measuring response to therapies.
“Current diagnostic tests are less than ideal for quantification of changes in tumor volume, which is key to managing the disease,” continued Allard. “As the MESOMARK results correlate with tumor volume*, it provides a much needed tool for monitoring patient status. It is our plan to collect additional data in the future to support the use of the test to detect mesothelioma.”

MESOMARK test are now making it possible – with a simple blood test -to monitor response to treatment and to detect recurrence following treatment. This provides an important head start to patients racing against this aggressive cancer. “The Meso Foundation is the national research funding, patient support and advocacy organization dedicated to eradicating mesothelioma as a life-threatening disease.
Those wishing to take part in MESOMARK testing will be asked to provide one or more samples of blood. The blood samples will then be sent to a national reference laboratory for testing. In conjunction with other clinical and laboratory data obtained by your doctor, decisions regarding your treatment and care may be simplified. You may discontinue testing at any time.

LINKS:
Diagnisis Mesothelioma